Black Friday Sale
Black Friday Sale
HomeNewsTrendsHealthDelta remains main COVID variant of concern, others now negligible in sequencing data: INSACOG

Delta remains main COVID variant of concern, others now negligible in sequencing data: INSACOG

Delta, which was first detected in India in October last year, led to the devastating second wave of the coronavirus pandemic in the country, which was at its peak in April and May.

November 11, 2021 / 16:18 IST
Image: Shutterstock

Delta variant of COVID-19 continues to be the main variant of concern and other variants of interest or concern are now negligible in sequencing data from India, the Indian Sars-CoV-2 Genomics Consortium (INSACOG) said.

The INSACOG, in a bulletin, said there is no change in the global scenario.

"Delta, including B.1.617.2 (AY) and AY.x sublineages, continues to be the main VOC globally. As per the latest WHO update, Delta has outcompeted other variants in most countries and there is now declining prevalence of other variants among SARS-CoV-2 sequences submitted to publicly available datasets or reported to WHO,” it said.

In India, it said, Delta (B.1.617.2 and AY.x) continues to be the main variant of concern (VOC).

"No new VOI or VOC are noted and other VOC and VOI other than Delta are now negligible in sequencing data from India,” it said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Delta, which was first detected in India in October last year, led to the devastating second wave of the coronavirus pandemic in the country, which was at its peak in April and May.

INSACOG, a consortium of 28 national laboratories, was set up in December 2020 to monitor the genomic variations in Sars-CoV-2, the COVID-19 causing virus.

A pan-India network, it functions under the Union health ministry.

Follow our full coverage of the coronavirus pandemic here.
PTI
first published: Nov 11, 2021 04:17 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347